Full history for every metric is available with a Kvantra account
OncoCyte Corporation (OCX)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 8 | 1 | 2 | 2 | 4 | 2 |
| Operating profit | $m | -51 | -50 | |||||
| Net profit | $m | -30 | -64 | -73 | -28 | -61 | -50 | -49 |
| EPS reported | $ | -1.65 | -1.49 | |||||
| Operating cashflow per share | $ | -0.73 | -0.73 | |||||
| Capex per share | $ | 0.00 | 0.03 | |||||
| FCF per share | $ | -0.73 | -0.70 | |||||
| Free cash flow | $m | -22 | -26 | |||||
| Net debt | $m | -8 | -18 | |||||
| Book value equity | $m | -31 | -21 | |||||
| Book value per share | $ | -1.03 | -0.58 | |||||
| Number of shares | m | 30.48 | 36.75 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -2.64 | -4.30 | |||||
| P/S LTM | x | 20.52 | 54.80 | |||||
| P/FCF LTM | x | -3.75 | -3.56 | |||||
| EV/EBITDA LTM | x | 34.19 | -3.61 | |||||
| EV/Sales LTM | x | 18.52 | 44.17 | |||||
| Earnings Yield LTM | % | -60.36% | -41.97% | |||||
| FCF Yield | % | -26.66% | -28.07% | |||||
| Quality | ||||||||
| ROE | % | 159.62% | 271.76% | |||||
| ROIC | % | -330.09% | -241.04% | |||||
| Operating margin | % | -1260.8% | -3011.9% | |||||
| Gross margin | % | 56.67% | 47.60% | |||||
| FCF/Sales | % | -547.08% | -1538.0% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +115.58% | -60.77% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -6.34 | -9.78 | |||||
| Net Debt/EBITDA | x | -3.68 | 0.74 | |||||
| EBIT/Net interest | x | 469.03 | 1,257.45 | |||||
| Net debt/market cap | % | -9.72% | -19.40% | |||||
| Net debt/Equity | x | 0.26 | 0.83 | |||||
| Gross debt/equity | x | -0.11 | -0.12 | |||||
Company overview
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
OncoCyte Corporation (OCX)
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free